Find in Library

At present, there are many types of drugs for clinical treatment of type 2 diabetes mellitus (T2DM) , there are differences in the hypoglycemic mechanisms and safety of traditional hypoglycemic drugs such as thiazolidinediones, sulfonylureas, biguanides, and insulin. In recent years, an assortment of new target drugs has emerged in an endless stream.New target drugs such as glucokinase activators, multi-site receptor agonists for GLP-1, GIP and glucagon, glucagon receptor inhibitors have gradually assembled the necessities of personalized clinical treatment through different mechanisms. This article reviews the current research progress of new target drugs for T2DM, and analyzes the advantages and disadvantages of clinical research of various new target drugs, in order to provide basic guidance for the clinical treatment of T2DM.